Skip to main content

Select Drug Profiles

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Long-Term Follow-Up of Chlorambucil plus Rituximab Combination as Frontline Therapy for Elderly and/or Unfit Patients with CLL, Including Risk Stratification

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Initial Results of a Multicenter, Phase II Study of Ibrutinib plus FCR (iFCR) as Frontline Therapy for Younger CLL Patients

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Outcomes of Ibrutinib Therapy by Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Updated Safety and Efficacy Data for Ibrutinib as First-Line Treatment in Older Patients with CLL or SLL

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

5-Year Ibrutinib Therapy in Treatment-Naïve Patients with Relapsed or Refractory CLL or SLL

Original Research

Clinical Characteristics and Unmet Need Among Patients with Atherosclerotic Cardiovascular Disease Stratified by Statin Use

Qing Huang, PhD, MHS, Michael Grabner, PhD, Robert J. Sanchez, PhD, Vincent J. Willey, PharmD, Mark J. Cziraky, PharmD, Swetha R. Palli, MS, Thomas P. Power, MD, FACC, MRCPI

Stakeholder Perspective

Using Statin Therapy to Reduce Atherosclerotic Cardiovascular Disease Risk

by Raymond L. Singer, MD, MMM, CPE

Page 104 of 244
Results 1031 - 1040 of 2438